Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of BridgeBio Pharma Inc (NASDAQ: BBIO) closed at $25.46 in the last session, up 2.08% from day before closing price of $24.94. In other words, the price has increased by $2.08 from its previous closing price. On the day, 1.59 million shares were traded. BBIO stock price reached its highest trading level at $26.15 during the session, while it also had its lowest trading level at $24.79.
Ratios:
We take a closer look at BBIO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.59 and its Current Ratio is at 4.59.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on September 04, 2024, initiated with a Overweight rating and assigned the stock a target price of $46.
On January 31, 2024, BMO Capital Markets started tracking the stock assigning a Market Perform rating and target price of $37.BMO Capital Markets initiated its Market Perform rating on January 31, 2024, with a $37 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 13 ’24 when KKR Genetic Disorder L.P. sold 5,800,000 shares for $25.75 per share. The transaction valued at 149,350,000 led to the insider holds 25,260,971 shares of the business.
KKR Genetic Disorder L.P. bought 5,800,000 shares of BBIO for $156,310,000 on Sep 13 ’24. On Aug 19 ’24, another insider, Kumar Neil, who serves as the Chief Executive Officer of the company, sold 27,389 shares for $24.69 each. As a result, the insider received 676,256 and left with 4,897,443 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 4787319808 and an Enterprise Value of 6079655424. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.85. Its current Enterprise Value per Revenue stands at 27.745 whereas that against EBITDA is -12.243.
Stock Price History:
Over the past 52 weeks, BBIO has reached a high of $44.32, while it has fallen to a 52-week low of $21.62. The 50-Day Moving Average of the stock is -2.86%, while the 200-Day Moving Average is calculated to be -14.57%.
Shares Statistics:
According to the various share statistics, BBIO traded on average about 1.94M shares per day over the past 3-months and 2249250 shares per day over the past 10 days. A total of 175.08M shares are outstanding, with a floating share count of 146.91M. Insiders hold about 21.87% of the company’s shares, while institutions hold 74.94% stake in the company. Shares short for BBIO as of 1726185600 were 19612818 with a Short Ratio of 10.10, compared to 1723680000 on 18018289. Therefore, it implies a Short% of Shares Outstanding of 19612818 and a Short% of Float of 16.059999.
